COMP <GO>
VYX vs TMO // ENTERPRISE SCALE & MARKET CAP
NCR Voyix Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: VYX 1
— TMO 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $8.48 (+3.16%) • MKT CAP: $1.13B
market-cap
$1.13B
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VYX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VYX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.10% | 9.30% | -8.20 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 77.1x | 30.4x | +46.70 | TMO | /valuation <GO> |
| Free Cash Flow Yield | -18.50% | 2.40% | -20.90 | TMO | /fcf-yield <GO> |
| Operating Margin | 1.00% | 17.40% | -16.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 2.30% | 15.10% | -12.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -4.60% | 3.90% | -8.50 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.16 | 4.50 | -3.34 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.4 | 62.9 | -6.50 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.0x | 36.3x | -19.30 | VYX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.13B | $262.22B | -$261.08B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VYX REV | TMO REV | VYX GROSS % | TMO GROSS % | VYX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.69B | $44.56B | — | — | -$210.0M | $6.29B |
| FY 2024 | $2.82B | $42.88B | — | — | -$162.0M | $7.27B |
| FY 2023 | $3.17B | $42.86B | — | — | $694.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VYX // BETA —
TMO // BETA 0.94